CytoTronics Receives $9.25M in Initial Seed Funding

Choate represented CytoTronics, a biotechnology company building a next-generation complementary metal-oxide-semiconductor (CMOS)-powered drug discovery platform, in its $9.25 million initial seed funding, which was led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures) and institutional investors. Choate was involved with the company from the beginning and negotiated the exclusive license with Harvard University to secure rights to the foundational IP. CytoTronics has announced that it will use the funding to advance its breakthrough platform that utilizes computer chip technology to conduct a suite of electrical and electrochemical cell-based assays.